The news that has been published over the last two days about gene therapy, the first such type of cancer has caused great controversy among public opinion, particularly cancer patients, prompting authorities in both the Arab Arab countries and Saudi Arabia to explain this concern. In response to questions about a new cancer drug, called Vitracafe.
It is also known as "Lauterkteinp". VITRAKFI is an effective drug in very limited types of carcinogenic tumors that carry genetic mutations and can not exceed 1 percent in some species, experts say. Experts have stressed that "Vitracafe" is not effective for patients with early stage cancer, or the second or third, but it is dedicated to patients in stage 4 cancer, the degree of tumor tumor spread in the body.
Experts have pointed out that the number of patients who may benefit from this drug is very limited due to the lack of these mutations. Moreover, this rate of response is also met with conventional cancer treatments, chemotherapy, radiation therapy and surgical procedures.
The Ministry of Health announced on Sunday evening a statement by the Saudi Press Agency on the waiver of the "accuracy" of the media and communication platforms on Vitraki and its treatment of cancer. Vitracave is not a substitute for three traditional cancer treatments, the ministry said.
It is also not fully treated, but only aims to control the spread of cancerous carcinoma in the body as long as possible. The ministry said the drug did not treat completely cancer of origin, as recently mentioned in the media, but aims to control cancer growth and spread as long as possible, rather than a replacement for surgical treatment and chemotherapy and radiation therapy.
The first cancer treatment in the world, its price is $ 393,600